PureTech Health (LON:PRTC) Trading Down 12.4% – Should You Sell?

PureTech Health plc (LON:PRTC)’s stock price traded down 12.4% during mid-day trading on Wednesday . The company traded as low as GBX 100.40 ($1.28) and last traded at GBX 103 ($1.32). 3,018,245 shares were traded during mid-day trading, an increase of 192% from the average session volume of 1,035,028 shares. The stock had previously closed at GBX 117.60 ($1.50).

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 455 ($5.81) price objective on shares of PureTech Health in a research report on Monday, December 16th.

PureTech Health Stock Down 12.4 %

The firm’s fifty day moving average is GBX 136.77 and its 200-day moving average is GBX 148.52. The company has a market capitalization of £309.39 million, a P/E ratio of -4.23 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.